BioLine RX Ltd Net Assets
BioLine RX Ltd net assets. Based on the latest financial reports, BioLine RX Ltd (BLRX) has net assets worth ILA16.51 Million ILA (≈ $44.26K USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA33.26 Million ≈ $89.16K USD) and total liabilities (ILA16.75 Million ≈ $44.90K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BLRX net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA16.51 Million |
| % of Total Assets | 49.64% |
| Annual Growth Rate | 3.07% |
| 5-Year Change | -65.71% |
| 10-Year Change | -33.34% |
| Growth Volatility | 78.93 |
Net Assets of BioLine RX Ltd (2005–2025)
Net assets of BioLine RX Ltd from 2005 to 2025. This chart illustrates how BioLine RX Ltd's net assets have evolved over time, based on quarterly financial data. See how leveraged is BioLine RX Ltd's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for BioLine RX Ltd (2005–2025)
The table below shows the annual net assets of BioLine RX Ltd from 2005 to 2025. For live market cap and overall valuation, see BioLine RX Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ILA23.35 Million ≈ $62.60K |
+73.46% |
| 2024-12-31 | ILA13.46 Million ≈ $36.09K |
+1.80% |
| 2023-12-31 | ILA13.22 Million ≈ $35.45K |
-73.99% |
| 2022-12-31 | ILA50.84 Million ≈ $136.30K |
-25.33% |
| 2021-12-31 | ILA68.09 Million ≈ $182.54K |
+209.06% |
| 2020-12-31 | ILA22.03 Million ≈ $59.06K |
-34.00% |
| 2019-12-31 | ILA33.38 Million ≈ $89.49K |
-19.22% |
| 2018-12-31 | ILA41.32 Million ≈ $110.78K |
-21.86% |
| 2017-12-31 | ILA52.88 Million ≈ $141.77K |
+50.97% |
| 2016-12-31 | ILA35.03 Million ≈ $93.91K |
-26.43% |
| 2015-12-31 | ILA47.61 Million ≈ $127.64K |
+49.88% |
| 2014-12-31 | ILA31.77 Million ≈ $85.16K |
+171.90% |
| 2013-12-31 | ILA11.68 Million ≈ $31.32K |
-21.96% |
| 2012-12-31 | ILA14.97 Million ≈ $40.14K |
-33.56% |
| 2011-12-31 | ILA22.53 Million ≈ $60.41K |
-82.92% |
| 2010-12-31 | ILA131.96 Million ≈ $353.78K |
+11.89% |
| 2009-12-31 | ILA117.94 Million ≈ $316.18K |
+50.46% |
| 2008-12-31 | ILA78.39 Million ≈ $210.15K |
-57.23% |
| 2007-12-31 | ILA183.25 Million ≈ $491.29K |
+14819.12% |
| 2006-12-31 | ILA-1.25 Million ≈ $-3.34K |
-109.75% |
| 2005-12-31 | ILA12.77 Million ≈ $34.22K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BioLine RX Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40108524500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
BioLine RX Ltd Net Assets Breakdown (December 2025)
BioLine RX Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA73.44 Million | 403.54% |
| Other Comprehensive Income | ILA18.19 Million | 99.95% |
| Other Components | ILA327.65 Million | 1800.31% |
| Total Equity | ILA18.20 Million | 100.00% |
BioLine RX Ltd Competitors by Market Cap
The table below lists competitors of BioLine RX Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PowerBank Corporation
NEO:PBK
|
$8.59 Million |
|
Holista Colltech Ltd
AU:HCT
|
$8.59 Million |
|
Comperia.pl S.A.
WAR:CPL
|
$8.59 Million |
|
Alkali Metals Limited
NSE:ALKALI
|
$8.59 Million |
|
AlphaTON Capital Corp.
NASDAQ:ATON
|
$8.58 Million |
|
JE Cleantech Holdings Ltd
NASDAQ:JCSE
|
$8.57 Million |
|
Vantage Corp
NYSE MKT:VNTG
|
$8.57 Million |
|
Aakash Exploration Services Limited
NSE:AAKASH
|
$8.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioLine RX Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,461,000 to 18,199,777, a change of 4,738,777 (35.2%).
- Net loss of 1,271,903 reduced equity.
- New share issuances of 13,894,000 increased equity.
- Other comprehensive income increased equity by 2,058,775.
- Other factors decreased equity by 9,942,095.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-1.27 Million | -6.99% |
| Share Issuances | ILA13.89 Million | +76.34% |
| Other Comprehensive Income | ILA2.06 Million | +11.31% |
| Other Changes | ILA-9.94 Million | -54.63% |
| Total Change | ILA- | 35.20% |
Book Value vs Market Value Analysis
This analysis compares BioLine RX Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 149.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.10x to 149.00x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | ILA10.60 | ILA1.10 | x |
| 2011-12-31 | ILA1.82 | ILA1.10 | x |
| 2012-12-31 | ILA0.88 | ILA1.10 | x |
| 2013-12-31 | ILA0.52 | ILA1.10 | x |
| 2014-12-31 | ILA0.98 | ILA1.10 | x |
| 2015-12-31 | ILA0.93 | ILA1.10 | x |
| 2016-12-31 | ILA0.62 | ILA1.10 | x |
| 2017-12-31 | ILA0.59 | ILA1.10 | x |
| 2018-12-31 | ILA0.38 | ILA1.10 | x |
| 2019-12-31 | ILA0.23 | ILA1.10 | x |
| 2020-12-31 | ILA0.09 | ILA1.10 | x |
| 2021-12-31 | ILA0.10 | ILA1.10 | x |
| 2022-12-31 | ILA0.07 | ILA1.10 | x |
| 2023-12-31 | ILA0.01 | ILA1.10 | x |
| 2024-12-31 | ILA0.01 | ILA1.10 | x |
| 2025-12-31 | ILA0.01 | ILA1.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioLine RX Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -99.58%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.25x
- Recent ROE (-6.99%) is above the historical average (-86.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 1.59% | 6.57% | 0.21x | 1.17x | ILA-11.10 Million |
| 2011 | -58.52% | 0.00% | 0.00x | 1.30x | ILA-15.44 Million |
| 2012 | -136.37% | 0.00% | 0.00x | 1.62x | ILA-21.91 Million |
| 2013 | -151.01% | 0.00% | 0.00x | 1.71x | ILA-18.81 Million |
| 2014 | -32.03% | 0.00% | 0.00x | 1.14x | ILA-13.35 Million |
| 2015 | -30.25% | 0.00% | 0.00x | 1.08x | ILA-19.16 Million |
| 2016 | -45.23% | 0.00% | 0.00x | 1.11x | ILA-19.34 Million |
| 2017 | -46.05% | 0.00% | 0.00x | 1.15x | ILA-29.64 Million |
| 2018 | -55.57% | 0.00% | 0.00x | 1.36x | ILA-27.09 Million |
| 2019 | -80.31% | 0.00% | 0.00x | 1.60x | ILA-30.14 Million |
| 2020 | -140.41% | 0.00% | 0.00x | 2.15x | ILA-33.13 Million |
| 2021 | -41.34% | 0.00% | 0.00x | 1.20x | ILA-34.95 Million |
| 2022 | -40.80% | 0.00% | 0.00x | 1.50x | ILA-25.83 Million |
| 2023 | -458.40% | -1262.79% | 0.08x | 4.83x | ILA-61.94 Million |
| 2024 | -68.50% | -31.86% | 0.74x | 2.89x | ILA-10.57 Million |
| 2025 | -6.99% | -99.58% | 0.03x | 2.25x | ILA-3.09 Million |
Industry Comparison
This section compares BioLine RX Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $90,874,556
- Average return on equity (ROE) among peers: -89.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioLine RX Ltd (BLRX) | ILA16.51 Million | 1.59% | 1.01x | $8.58 Million |
| BioLight Life Sciences Ltd (BOLT) | $77.80 Million | 84.05% | 0.16x | $7.08 Million |
| Bonus Biogroup (BONS) | $6.96 Million | -399.97% | 2.36x | $56.36 Million |
| Can Fite Biopharma Ltd (CANF) | $6.24 Million | -122.28% | 0.60x | $2.95 Million |
| Clal Biotechnology Industries Ltd (CBI) | $497.85 Million | -30.96% | 0.24x | $9.63 Million |
| Compugen (CGEN) | $31.89 Million | -44.16% | 0.78x | $159.88 Million |
| DNA Biomed Solns (DNA) | $101.47 Million | 21.78% | 0.03x | $38.30 Million |
| Enlivex Therapeutics Ltd (ENLV) | $75.00K | -305.33% | 1.08x | $126.77K |
| Evogene (EVGN) | $124.75 Million | -7.12% | 0.10x | $2.68 Million |
| Kadimastem Ltd (KDST) | $-29.15 Million | 0.00% | 0.00x | $22.18 Million |
About BioLine RX Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more